Advertisement

Disorders with Excessive Muscle Contraction: Candidates for Treatment with Intramuscular Botulinum Toxin (“Botox”)

  • Mitchell F. Brin
  • Andrew Blitzer
  • Celia Stewart
  • Zachary Pine
  • Joanne Borg-Stein
  • James Miller
  • Nagalapura S. Viswanath
  • David B. Rosenfield

Abstract

The initial clinical use of local injections of type A botulinum toxin (botox) was for the treatment of strabismus.1 The intended goal was to block acetylcholinergic neuromuscular junctions and rebalance neural input to the extraocular rectus muscles; this enhanced convergence.2 Several drugs, including alpha-bungarotoxin, had been considered prior to botox, but each had limitations. These included lack of selectivity, undesired side effects, short duration of action, and substantial antigenicity. Botox has the advantage of being apotent neuromuscular blocking agent while not suffering as many limitations as other putative therapeutic agents.

Keywords

Botulinum Toxin Essential Tremor Cervical Dystonia Hemifacial Spasm Intrathecal Baclofen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brin MF. Interventional neurology: treatment of neurological conditions with local injections of botulinum toxin. Arch Neurobiol 1991; 54 (Supp13): 7–23.Google Scholar
  2. 2.
    Sellin LC. The action of botulinum toxin at the neuromuscular junction. Med Biol 1981; 59: 11–20.PubMedGoogle Scholar
  3. 3.
    Quinn N, Hallett M. Dose standardisation of botulinum toxin [letter]. Lancet 1989; 1: 964.PubMedCrossRefGoogle Scholar
  4. 4.
    Quinn NP, Hallett M. Dose standardisation of botulinum toxin-published erratum correction. Lancet 1989; 1: 1989.Google Scholar
  5. 5.
    Nagamine T, Kaji R, Hamano T, Kimura J. Treatment of focal dystonia with botulinum toxin. Clin Neurol 1991; 31: 32–37.Google Scholar
  6. 6.
    Scott AB. Clostridial toxins as therapeutic agents. In: Simpson LL, ed. Botulinum neurotoxin and tetanus toxin. New York: Academic Press, 1989: 399–412.Google Scholar
  7. 7.
    Klawans HL. Taking a risk. In: Trials of an expert witness: tales of clinical neurology and the law. Boston: Little Brown, 1991: 93–94.Google Scholar
  8. 8.
    AAN. Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1990; 40: 1332–1336.CrossRefGoogle Scholar
  9. 9.
    AAO Statement. Botulinum-A toxin for ocular muscle disorders. Lancet 1986; 1: 76–77.Google Scholar
  10. 10.
    AAO Statement. Botulinum toxin therapy of eye muscle disorders. Safety and effectiveness. American Academy of Ophthalmology. Ophthalmology 1989; Part 2 (Sept): 37–41.Google Scholar
  11. 11.
    AAO-HNS. American Academy of Otolaryngology-Head and Neck Surgery Policy Statement: Botox for spasmodic dysphonia. AAO-HNS Bulletin 1990; 9 (12/December): 8.Google Scholar
  12. 12.
    NIH Censensus Development Conference Consensus Statement. Clinical use of botulinum toxin. N I H Cons Dev Conf 1990; 8: 12–14.Google Scholar
  13. 13.
    Jankovic J, Brin M. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324: 1186–1194.PubMedCrossRefGoogle Scholar
  14. 14.
    Brin MF, Blitzer A, Stewart C, Fahn S. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin: review and technical aspects. In: Blitzer A, Brin MF, Sasaki CT, Fahn S, Harris KS, eds. Neurological disorders of the larynx. New York: Thieme, 1992:214228.Google Scholar
  15. 15.
    Parkinson’s Disease and Movement Disorders. Baltimore:Urban and Schwarzenberg, 1988:Google Scholar
  16. 16.
    Weiner WJ, Lang AE. Movement disorders: a comprehensive survey. Mount Kisco:Futura, 1989:Google Scholar
  17. 17.
    Garrison SJ, Rolak LA, Dodaro RR, O’Callighan AJ. Rehabilitation of the stroke patient. In: DeLisa JA, ed. Rehabilitation Medicine: Principles and Practice. Philadelphia: Lippincott, 1988: 565.Google Scholar
  18. 18.
    Whyte J, Rosenthal M. Rehabilitation of the patient with head injury. In: DeLisa JA, ed. Rehabilitation medicine: Principles and Practice. Philadelphia: Lippincott, 1988: 585.Google Scholar
  19. 19.
    Cleeves LB, Findley LJ. Tremors. Med Clin North Am 1989; 73: 1307–1319.Google Scholar
  20. 20.
    Capildeo R, Findley LJ. Classification of tremor. In: Findley LJ, Capildeo R, eds. Movement disorders: tremor. New York: Oxford University Press, 1984: 3–13.Google Scholar
  21. 21.
    Bloodstein O. A Handbook on Stuttering. Chicago:National Easter Seal Society, 1987:Google Scholar
  22. 22.
    Fahn S. The varied clinical expressions of dystonia. Neurol Clin 1984; 2: 541–554.PubMedGoogle Scholar
  23. 23.
    Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ, III. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988; 3: 188–194.PubMedCrossRefGoogle Scholar
  24. 24.
    Ozelius L, Kramer PL, Moskowitz CB, et al. Human gene for torsion dystonia located on chromosome 9q32-q34. Neuron 1989; 2: 1427–1434.PubMedCrossRefGoogle Scholar
  25. 25.
    Kramer PL, de Leon D, Ozelius L, et al. Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32–34. Ann Neurol 1990; 27: 114–120.PubMedCrossRefGoogle Scholar
  26. 26.
    Wilhelmsen KC, Weeks DE, Nygaard TG, et al. Genetic mapping of the “Lubag” (X-linked dystonia-parkinsonism) in a Filipino kindred to the pericentromeric region of the X chromosome. Ann Neurol 1991; 29: 124–131.PubMedCrossRefGoogle Scholar
  27. 27.
    Fahn S, Moskowitz C. X-Linked recessive dystonia and parkinsonism in Filipino males. Ann Neurol 1988; 24: 179.Google Scholar
  28. 28.
    Lee LV, Kupke KG, Caballar Gonzaga F, Hebron Ortiz M, Muller U. The phenotype of the X-linked dystonia-parkinsonism syndrome. An assessment of 42 cases in the Philippines. Medicine (Balt) 1991; 70: 179–187.CrossRefGoogle Scholar
  29. 29.
    Kupke KG, Lee LV, Muller U. Assignment of the X-linked torsion dystonia gene to Xq21 by linkage analysis. Neurology 1990; 40: 1438–1442.PubMedCrossRefGoogle Scholar
  30. 30.
    Kupke KG, Lee LV, Viterbo GH, Arancillo J, Donlon T, Muller U X-linked recessive torsion dystonia in the Philippines. Am J Med Genet 1990; 36: 237–242.PubMedCrossRefGoogle Scholar
  31. 31.
    Kwiatkowski DJ, Nygaard TG, Schuback DE, et al. Identification of a highly polymorphic microsatellite VNTR within the argininosuccinate synthetase locus: exclusion of the dystonia gene on 9q32–34 as the cause of dopa-responsive dystonia in a large kindred. Am J Hum Genet 1991; 48: 121–128.PubMedGoogle Scholar
  32. 32.
    Obeso JA, Gimenez Roldan S. Clinicopathological correlation in symptomatic dystonia. Adv Neurol 1988; 50: 113–122.PubMedGoogle Scholar
  33. 33.
    Marsden CD, Obeso JA, Zarranz JJ, Lang AE. The anatomical basis of symptomatic hemidystonia. Brain 1985; 108: 463–483.PubMedCrossRefGoogle Scholar
  34. 34.
    Narbona J, Obeso JA, Tunon T, Martinez Lage JM, Marsden CD. Hemidystonia secondary to localized basal ganglia tumour. J Neurol Neurosurg Psychiatry 1984; 47: 704–709.PubMedCrossRefGoogle Scholar
  35. 35.
    Jankovic J, Patel SC. Blepharospasm associated with brainstem lesions. Neurology 1983; 33: 1237–1240.PubMedCrossRefGoogle Scholar
  36. 36.
    Zweig RM, Hedreen JC, Jankel WR, Casanova MF, Whitehouse PJ, Price DL. Pathology in brainstem regions of individuals with primary dystonia. Neurology 1988; 38: 702–706.PubMedCrossRefGoogle Scholar
  37. 37.
    Hedreen JC, Zweig RM, DeLong MR, Whitehouse PJ, Price DL. Primary dystonias: a review of the pathology and suggestions for new directions of study. Adv Neurol 1988; 50: 123–132.PubMedGoogle Scholar
  38. 38.
    Jankovic J, Svendsen CN, Bird ED. Brain neurotransmitters in dystonia. N Engl J Med 1987; 316: 278–279.CrossRefGoogle Scholar
  39. 39.
    de Yebenes JG, Brin MF, Mena MA, et al. Neurochemical findings in neuroacanthocytosis. Mov Disord 1988; 3: 300–312.PubMedCrossRefGoogle Scholar
  40. 40.
    Tempel LW, Perlmutter JS. Abnormal vibration-induced cerebral blood flow responses in idiopathic dystonia. Brain 1990; 113: 691–707.PubMedCrossRefGoogle Scholar
  41. 41.
    Perlmutter JS, Raichle ME. Pure hemidystonia with basal ganglion abnormalities on positron emission tomography. Ann Neurol 1984; 15: 228–233.PubMedCrossRefGoogle Scholar
  42. 42.
    Playford ED, Rassingham RE, Marsden CD, Brooks DJ. Abnormal activation of striatum and dorsolateral prefontal cortex in dystonia. Neurology 1992; 42 (Suppl 3): 377. (Abstract)Google Scholar
  43. 43.
    Takahashi H, Snow B, Waters C, et al. Evidence for nigrostriatal lesions in Lubag (X-linked dystoniaparkinsonism in the Philippines). Neurology 1992; 42 (Suppl 3): 441. (Abstract)Google Scholar
  44. 44.
    Nygaard TG, Trugman JM, de Yebenes JG, Fahn S. Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family. Neurology 1990; 40: 66–69.PubMedCrossRefGoogle Scholar
  45. 45.
    Fletcher NA, Holt IJ, Harding AE, Nygaard TG, Mallet J, Marsden CD. Tyrosine hydroxylase and levodopa responsive dystonia. J Neurol Neurosurg Psychiatry 1989; 52: 112–114.PubMedCrossRefGoogle Scholar
  46. 46.
    Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986; 36: 160–164.PubMedCrossRefGoogle Scholar
  47. 47.
    Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 1988; 3: 46–60.PubMedCrossRefGoogle Scholar
  48. 48.
    Bressman SB, Greene PE. Treatment of hyperkinetic movement disorders. Neurol Clin 1990; 8: 51–75.PubMedGoogle Scholar
  49. 49.
    Digre K, Corbett JJ. Hemifacial spasm: differential diagnosis, mechanism, and treatment. Adv Neurol 1988; 49: 151–176.PubMedGoogle Scholar
  50. 50.
    Digre KB, Corbett JJ, Smoker WR, McKusker S. CF and hemifacial spasm. Neurology 1988; 38: 1111–1113.PubMedCrossRefGoogle Scholar
  51. 51.
    Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987; 2: 237–254.PubMedCrossRefGoogle Scholar
  52. 52.
    Biglan AW, May M, Bowers RA. Management of facial spasm with Clostridium botulinum toxin, type A (Oculinum). Arch Otolaryngol Head Neck Surg 1988; 114: 1407–1412.PubMedCrossRefGoogle Scholar
  53. 53.
    Carruthers J, Stubbs HA. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. Can J Neurol Sci 1987; 14: 42–45.PubMedGoogle Scholar
  54. 54.
    Elston JS. Botulinum toxin therapy for involuntary facial movement. Eye 1988; 2: 12–15.PubMedCrossRefGoogle Scholar
  55. 55.
    Kraft SP, Lang AE. Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin. Can Med Assoc J 1988; 139: 837–844.Google Scholar
  56. 56.
    Newman NM. Chemical denervation for hemifacial spasm. West J Med 1986; 145: 520.PubMedGoogle Scholar
  57. 57.
    Savino PJ, Sergott RC, Bosley TM, Schatz NJ. Hemifacial spasm treated with botulinum A toxin injection. Arch Ophthalmol 1985; 103: 1305–1306.PubMedCrossRefGoogle Scholar
  58. 58.
    Roggenkamper P, Laskawi R, Damenz W, Schroder M, Nubgens Z. Botulinus-toxin-behandlung bei synkinesien nach fazialisparese. HNO 1990; 38: 295–297.PubMedGoogle Scholar
  59. 59.
    Iwashige H, Maruo T. [Treatment of blepharospasm and hemifacial spasm with botulinum A toxin (Oculinum)]. Nippon Ganka Gakkai Zasshi 1988; 92: 1637–1643.PubMedGoogle Scholar
  60. 60.
    Kraft SP, Lang AE. Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculation. Can J Neurol Sci 1988; 15: 276–280.PubMedGoogle Scholar
  61. 61.
    Saraux H. [Treatment of blepharospasm and facial hemispasm by injection of botulinum toxin]. J Fr Ophthalmol 1988; 11: 237–240.Google Scholar
  62. 62.
    Tolosa E, Marti MJ, Kulisevsky J. Botulinum toxin injection therapy for hemifacial spasm. Adv Neurol 1988; 49: 479–491.PubMedGoogle Scholar
  63. 63.
    Marti MJ, Kulisevsky J, Tolosa E. [Treatment of dystonic blepharospasm and hemifacial spasm with botulinum toxin: preliminary studies]. Med Clin (Barc) 1987; 89: 321–323.Google Scholar
  64. 64.
    Elston JS. Botulinum toxin treatment of hemifacial spasm. J Neurol Neurosurg Psychiatry 1986; 49: 825–829.CrossRefGoogle Scholar
  65. 65.
    Arthurs B, Flanders M, Codere F, Gauthier S, Dresner S, Stone L. Treatment of blepharospasm with medication, surgery and type A botulinum toxin. Can J Ophthalmol 1987; 22: 24–28.PubMedGoogle Scholar
  66. 66.
    Carta A, Stocchi F, Berardelli A, Bramante L, Viselli F. Botulinum toxin therapy for focal dystonias. New Trends in Ophthalmology 1989; 3: 68.Google Scholar
  67. 67.
    Erbguth F, Claus D, Neundorfer B. Treatment of facial-cervical dystonia and hemifacial spasm with botulinum-toxin A. New Trends in Ophthalmology 1989; 3: 69.Google Scholar
  68. 68.
    Geller BD, Hallett M, Ravits J. Botulinum toxin therapy in hemifacial spasm: Clinical and electrophysiologic studies. Muscle Nerve 1989; 12: 716–722.CrossRefGoogle Scholar
  69. 69.
    Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990; 53: 633–639.PubMedCrossRefGoogle Scholar
  70. 70.
    Gresty MA, Findley LJ. Definition, analysis and genesis of tremor. In: Findley LJ, Capildeo R, eds. Movement disorders: tremor. New York: Oxford University Press, 1984: 15–26.Google Scholar
  71. 71.
    Hubble JP, Busenbark KL, Koller WC. Essential tremor. Clin Neuropharm 1989; 12: 453–482.CrossRefGoogle Scholar
  72. 72.
    Busenbark KL, Nash J, Nash S, Hubble JP, Koller WC. Is essential tremor benign? Neurology 1991; 41: 1982–1983.PubMedCrossRefGoogle Scholar
  73. 73.
    Hariz MI. Correlation between clinical outcome and size and site of the lesion in computed tomography guided thalamotomy and pallidotomy. Stereotact Funct Neurosurg 1990; 54–55: 172–185.CrossRefGoogle Scholar
  74. 74.
    Kelly PJ. Applications and methodology for contemporary stereotactic surgery. Neurol Res 1986; 8: 212.Google Scholar
  75. 75.
    Jankovic J, Schwartz K. Botulinum toxin treatment of tremors. Neurology 1991; 41: 1185–1188.PubMedCrossRefGoogle Scholar
  76. 76.
    Zager EL. Neurosurgical management of spasticity, rigidity, and tremor. Neurol Clin 1987; 5: 631–647.PubMedGoogle Scholar
  77. 77.
    Davidoff RA. Skeletal muscle tone and the misunderstood stretch reflex. Neurology 1992; 42: 951.PubMedCrossRefGoogle Scholar
  78. 78.
    Cartlidge NEF, Hudgson P, Weightman D. A comparison of baclogen and diazepam in the treatment of spasticity. J Neurol Sci 1974; 23: 17.PubMedCrossRefGoogle Scholar
  79. 79.
    Feldman RG, Kelly Hayes M, Conomy JP. Baclofen for spasticity in multiple sclerosis; double blind crossover and three year study. Neurology 1978; 28: 1094.PubMedCrossRefGoogle Scholar
  80. 80.
    Sawa GM, Paty DW. The use of baclofen in treatment of spasticity in multiple sclerosis. J Neurol Sci 1979; 6: 351.Google Scholar
  81. 81.
    Schmidt RT, Lee RH, Spehlemann R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1976; 39: 350.PubMedCrossRefGoogle Scholar
  82. 82.
    Rinne UK. Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy. Curr Ther Res 1980; 28: 827.Google Scholar
  83. 83.
    Stein R, Nordal HJ, Offedal SI, Slettebo M. The treatment of spasticity in multiple sclerosis; a double blind clinical trial of a new anti spastic drug tizanidine compared with baclofen. Acta Neurol Scand 1987; 75: 190.CrossRefGoogle Scholar
  84. 84.
    Bass B, Weinshenker B, Rice GP, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988; 15: 15–19.PubMedGoogle Scholar
  85. 85.
    Keenan MAE, Todderud EP, Henderson R, Botte M. Management of intrinsic spasticity in the hand with phenol injection or neurectomy of the motor branch of the ulnar nerve. Journal of Hand Surgery 1987; 12A: 734.PubMedCrossRefGoogle Scholar
  86. 86.
    Garland DE, Lilting M, Keenan MA. Percutaneous phenol blocks to motor points of spastic forearm muscles in head-injured patients. Arch Phys Med Rehabil 1984; 65: 243.PubMedGoogle Scholar
  87. 87.
    Nathan PW. Intrathecal phenol to relieve spasticity in paraplegia. Lancet 1959; 2: 1099.PubMedCrossRefGoogle Scholar
  88. 88.
    Kelly RE, Gautier-Smith PC. Intrathecal phenol in the treatment of reflex spasms and spasticity. Lancet 1959; 2: 1102.PubMedCrossRefGoogle Scholar
  89. 89.
    Penn RD, Kroin JS. Continuous intrathecal baclofen for severe spasticity. Lancet 1985; 2: 125.PubMedCrossRefGoogle Scholar
  90. 90.
    Penn RD, Kroin JS. Long-term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg 1987; 66: 181.PubMedCrossRefGoogle Scholar
  91. 91.
    Penn RD, Savoy SM, Corcos DM. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517.PubMedCrossRefGoogle Scholar
  92. 92.
    Snow BJ, Tsui JK, Bhatt MR, Varelas M, Hashimoto SA, Caine DB. Treatment of spasticity with botulinum toxin: A double-blind study. Ann Neurol 1990; 28: 512–515.PubMedCrossRefGoogle Scholar
  93. 93.
    Das TK, Park DM. Botulinum toxin in treating spasticity. Br J Clin Pract 1989; 43: 401–403.PubMedGoogle Scholar
  94. 94.
    Das TK, Park DM. Effect of treatment with botulinum toxin on spasticity. Postgrad Med J 1989; 65: 208–210.PubMedCrossRefGoogle Scholar
  95. 95.
    Borg-Stein J, Pine ZM, Miller J, Brin MF. Botulinum toxin for treatment of spasticity in multiple sclerosis. Association of Academic Physiatrist, Orlando, Florida, 1992; ( Abstract )Google Scholar
  96. 96.
    Wiegand H, Erdmann G, Wellhoener 11H. 125I labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1976; 292: 161–165.PubMedCrossRefGoogle Scholar
  97. 97.
    Eldridge M. A History of the Treatment of Speech Disorders. London:Livingston, 1968:Google Scholar
  98. 98.
    Schnell H. Sex differences in relation to stuttering: part 1. J Speech Hear Disord 1946; 11: 297–298.Google Scholar
  99. 99.
    Kopp GA. Metabolic studies of stutterers: I. Biochemical study of blood composition. Speech Monogr 1934; 1: 117–132.CrossRefGoogle Scholar
  100. 100.
    Orton S, Travis LE. Studies in stuttering: IV. Studies of action currents in stutterers. Arch Neurol 1929; 21: 61–68.CrossRefGoogle Scholar
  101. 101.
    Karlin 1W, Strazzulla M. Speech and Language problems of mentally deficient children. J Speech Hear Disord 1952; 17: 286–294.Google Scholar
  102. 102.
    Ingham R. Stuttering and Behavior Therapy: Current Status and Experimental Foundations. San Diego:College Hill Press, 1984:Google Scholar
  103. 103.
    Webster RL, Lubker BB. Interrelationships among fluency producing variables in stuttered speech. J Speech Hear Res 1968; 11: 754–66.PubMedGoogle Scholar
  104. 104.
    Webster RL, Lubker BB. Masking of auditory feedback in stutterers’ speech. J Speech Hear Res 1968; 11: 221–223.PubMedGoogle Scholar
  105. 105.
    Freeman FJ, Ushijima T. Laryngeal muscle activity during stuttering. J Speech Hear Res 1978; 21: 538–562.PubMedGoogle Scholar
  106. 106.
    Nudelman HB, Herbrick KE, Hoyt BD, Rosenfield DB. Phonatory response times of stutterers and fluent speakers to frequency-modulated tones. J Acoust Soc Am 1992; (In Press)Google Scholar
  107. 107.
    Ludlow CL, Naunton RF, Fujita M, Sedory SE. Spasmodic dysphonia: botulinum toxin injection after recurrent nerve surgery. Otolaryngol Head Neck Surg 1990; 102: 122–131.PubMedGoogle Scholar
  108. 108.
    Ludlow CL, Naunton RF, Sedory SE, Schulz GM, Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 1988; 38: 1220–1225.PubMedCrossRefGoogle Scholar
  109. 109.
    Zwimer P, Murry T, Swenson M, Woodson G. Acoustic changes in spasmodic dysphonia after botulinum toxin injection. J Voice 1991; 5: 78–84.CrossRefGoogle Scholar
  110. 110.
    Pierard GE, Lapiere CM. The microanatomical basis of facial frown lines. Arch Dermatol 1991; 125: 1090–1092.CrossRefGoogle Scholar
  111. 111.
    Ellenbogen R, Wethe J, Jankauskas S, Collini F. Curette fat sculpture in rhytidectomy: improving the nasolabial and labiomandibular folds. Plast Reconstr Surg 1991; 88: 433–442.PubMedCrossRefGoogle Scholar
  112. 112.
    Ezrokhin VM. Removal of wrinkles and redundant skin in the region of the forehead. Acta Chir Plast 1991; 33: 1–7.PubMedGoogle Scholar
  113. 113.
    Horibe EK, Horibe K, Yamaguchi CT. Pronounced nasolabial fold: A surgical correction. Aesth Plast Surg 1989; 13: 99–103.CrossRefGoogle Scholar
  114. 114.
    Rafaty FM, Cochran J. A technique of nasalabioplasty. Laryngoscope 1978; 88: 95–99.PubMedGoogle Scholar
  115. 115.
    Riefkohl R. The nasolabial fold lift. Ann Plast Surg 1985; 15: 1–6.PubMedCrossRefGoogle Scholar
  116. 116.
    Webster R, Kattner MD, Smith RC. Injectable collagen for augmentation of facial areas. Arch Otolaryngol 1984; 110: 652–656.PubMedCrossRefGoogle Scholar
  117. 117.
    Kaplan EN, Races E, Tolleth H. Clinical utilization of injectable collagen. Ann Plast Surg 1983; 10: 437.PubMedCrossRefGoogle Scholar
  118. 118.
    Matti BA, Nicolle FV. Clinical use of zyplast in correction of age and disease related contour deficiencies of the face. Aesth Plast Surg 1990; 14: 227–234.CrossRefGoogle Scholar
  119. 119.
    Milliken C, Rosen T, Monheit G. Treatment of depressed cutaneous scars with gelatin matrix implant: A multicenter study. J Am Acad Dermatol 1989; 16: 1155–1162.Google Scholar
  120. 120.
    McKinney P, Cook JQ. Liposuction and the treatment of nasolabial folds. Aesth Plast Surg 1989; 13: 167–171.CrossRefGoogle Scholar
  121. 121.
    Pollack SV. Silicone, fibrel and collagen implantation for facial lines and wrinkles. J Dermatol Surg Oncol 1990; 16: 957–961.PubMedCrossRefGoogle Scholar
  122. 122.
    Blitzer A, Brin MF, Keen MS. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1992; (In Press)Google Scholar
  123. 123.
    Clark RP, Berris CE. Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg 1989; 84: 353–355.PubMedCrossRefGoogle Scholar
  124. 124.
    Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with botulinum A exotoxin. J Dermatol Surg Oncol 1992; 18: 17–21.PubMedCrossRefGoogle Scholar
  125. 125.
    Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusorsphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139: 919–922.PubMedGoogle Scholar
  126. 126.
    Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990; 71: 24–26.PubMedGoogle Scholar
  127. 127.
    Hallan RI, Williams NS, Melling J, Waldron DJ, Womack NR, Morrison JF. Treatment of anismus in intractable constipation with botulinum A toxin. Lancet 1988; 2: 714–717.PubMedCrossRefGoogle Scholar
  128. 128.
    Ludlow CL, Hallett M, Sedory SE, Fujita M, Naunton RF. The pathophysiology of spasmodic dysphonia and its modification by botulinum toxin. In: Berardelli A, Benecke R, Manfredi M, Marsden CM, eds. Motor Disturbances II. New York: Academic Press, 1990: 273–288.CrossRefGoogle Scholar
  129. 129.
    Brin MF, Fahn S, Moskowitz CB, et al. Injections of botulinum toxin for the treatment of focal dystonia. Neurology 1986; 36 (Suppl 1): 120. (Abstract)Google Scholar
  130. 130.
    Blitzer A, Brin MF, Fahn S, Lange D, Lovelace RE. Botulinum toxin (BOTOX) for the treatment of “spastic dysphonia” as part of a trial of toxin injections for the treatment of other cranial dystonias [letter]. Laryngoscope 1986; 96: 1300–1301.PubMedGoogle Scholar
  131. 131.
    Lange DJ, Warner C, Brin MF, List T, Fahn S, Lovelace R. Botulinum toxin therapy: Distant effects on neuromuscular transmission [abstract]. Muscle Nerve 1985; 8: 624.Google Scholar
  132. 132.
    Sanders DB, Massey EW, Buckley EC. EMG monitoring of botulinum toxin in blepharospasm. Neurology 1985; 35 (Suppl 1): 272. (Abstract)Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Mitchell F. Brin
    • 1
  • Andrew Blitzer
    • 2
  • Celia Stewart
    • 1
    • 2
  • Zachary Pine
    • 3
  • Joanne Borg-Stein
    • 4
  • James Miller
    • 1
  • Nagalapura S. Viswanath
    • 5
  • David B. Rosenfield
    • 5
  1. 1.Department of NeurologyColumbia Presbyterian Medical CenterNew YorkUSA
  2. 2.OtolaryngologyColumbia Presbyterian Medical CenterNew YorkUSA
  3. 3.Rehabilitation MedicineColumbia University College of Physicians and Surgeons, Columbia Presbyterian Medical CenterNew YorkUSA
  4. 4.Department of Rehabilitation MedicineTufts UniversityBostonUSA
  5. 5.Stuttering Center Speech Motor-Control Laboratory, Department of NeurologyBaylor College of Medicine & the Methodist HospitalHoustonUSA

Personalised recommendations